Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-10. (Cancelled)

11. (Currently amended) A compound of formula (IIB)



(IIB)

or a salt ~~or prodrug~~ thereof

where

X is O, or S, S(O) or $S(O)_2$, NH or NR^8 where R^8 is hydrogen or C_{1-6}alkyl,

Z is O or S,

n is an integer of from 1 to 6 and R^9 is hydrogen,

or n is 0 or an integer of from 1 to 6 and R^9 is ethenyl, optionally substituted phenyl, optionally substituted pyridyl or optionally substituted furanyl where optional substituents for R^9 groups are C_{1-3}alkoxy, C_{1-3}alkyl, halo or nitro,

R^6 and R^7 are independently selected from hydrogen, halo, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}alkoxymethyl, di(C_{1-4}alkoxy)methyl, C_{1-4}alkanoyl, trifluoromethyl, cyano, amino, C_{2-5}alkenyl, C_{2-5}alkynyl, a phenyl group, a benzyl group or a 5-6-membered heterocyclic group with 1-3 heteroatoms, selected independently from O, S and N, which heterocyclic group may be aromatic or non-aromatic and may be saturated and linked via a ring carbon or nitrogen atom or unsaturated and linked via a ring carbon atom, and which phenyl, benzyl or heterocyclic group may bear on one or more ring carbon atoms up to 5 substituents selected from hydroxy, halogeno, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3}alkanoyloxy, trifluoromethyl, cyano, amino, nitro, C_{2-4}alkanoyl, C_{1-4}alkanoylamino, C_{1-4}alkoxycarbonyl, C_{1-4}alkylsulphanyl, C_{1-4}alkylsulphinyl,

C_{1-4}alkylsulphonyl, carbamoyl, N-C_{1-4}alkylcarbamoyl, N,N-di(C_{1-4}alkyl)carbamoyl, aminosulphonyl, N-C_{1-4}alkylaminosulphonyl, N,N-di(C_{1-4}alkyl)aminosulphonyl, C_{1-4}alkylsulphonylamino, and a saturated heterocyclic group selected from morpholino, thiomorpholino, pyrrolidinyl, piperazinyl, piperidinyl, imidazolidinyl and pyrazolidinyl, which saturated heterocyclic group may bear 1 or 2 substituents selected from oxo, hydroxy, halogeno, C_{1-3}alkyl, C_{1-3}alkoxy, C_{1-3}alkanoyloxy, trifluoromethyl, cyano, amino, nitro and C_{1-4}alkoxycarbonyl, R^1 is hydrogen, R^4 is hydrogen, halo, C_{1-4}alkyl or C_{1-4}alkoxy ~~and n is 0, or an integer of from 1 to 6~~,

R^{66} is halo, cyano, nitro, trifluoromethyl, C_{1-3}alkyl, $-NR^{12}R^{13}$ [(])wherein R^{12} and R^{13}, which may be the same or different, each represents hydrogen or C_{1-3}alkyl, or a group $-X^1R^{14}$ wherein X^1 represents a direct bond, -O-, $-CH_2-$, -OC(O)-, -C(O)-, -S-, -SO-, $-SO_2-$, $-NR^{15}C(O)-$, $-C(O)NR^{16}-$, $-SO_2NR^{17}-$, $-NR^{18}SO_2-$ or $-NR^{19}-$ wherein R^{15}, R^{16}, R^{17}, R^{18} and R^{19} each independently represents hydrogen, C_{1-3}alkyl or C_{1-3}alkoxyC_{2-3}alkyl, and R^{14} is hydrogen or C_{1-5}alkyl which may be unsubstituted or which may be substituted with one or more groups selected from hydroxy, oxiranyl, fluoro, chloro, bromo and amino including C_{1-3}alkyl and trifluoromethyl; or $-R^9R^{38}$ and wherein R^{38} represents a pyridone group, a phenyl group or a 5-6-membered aromatic heterocyclic group linked via carbon or nitrogen with 1-3 heteroatoms selected from O, N and S, which pyridone, phenyl or aromatic heterocyclic group may carry up to 5 substituents selected from hydroxy, nitro, halogeno, amino, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}hydroxyalkyl, C_{1-4}aminoalkyl, C_{1-4}alkylamino, C_{1-4}hydroxyalkoxy, oxo, cyanoC_{1-4}alkyl, cyclopropyl, C_{1-4}alkylsulphonylC_{1-4}alkyl, C_{1-4}alkoxycarbonyl, di(C_{1-4}alkyl)amino, C_{1-4}alkylaminoC_{1-4}alkyl, C_{1-4}alkanoyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkoxy, di(C_{1-4}alkyl)aminoC_{1-4}alkoxy, carboxy, carboxamido, trifluoromethyl, cyano, $-C(O)NR^{39}R^{40}$, $-NR^{41}C(O)R^{42}$ wherein R^{39}, R^{40}, R^{41} and R^{42}, which may be the same or different, each represents hydrogen, C_{1-4}alkyl, hydroxyC_{1-4}alkyl or C_{1-3}alkoxyC_{2-3}alkyl and a group $-(-O-)_f(C_{1-4}alkyl)_g$ringD wherein f is 0 or 1, g is 0 or 1 and ring D is a cyclic group selected from C_{3-6}cycloalkyl, aryl or 5-6-membered saturated or unsaturated heterocyclic group with 1-2 heteroatoms, selected independently from O, S and N, which cyclic group may bear one or more substituents selected from halo and C_{1-4}alkyl; and wherein R^9 is a C_{1-6}alkylene group optionally substituted by one or more substituents selected from hydroxy, halogeno and amino ;

and R^{67} is C_{1-6}alkoxy substituted with a group X^1R^{38} wherein X^1 and R^{38} are as defined above or R^{67} is 3-morpholinopropoxy.

12. (Previously presented) A method of preparing a compound according to claim 11, which comprises reacting a compound of formula (VII)



(VII)

where $R^{1'}$, $R^{2'}$, $R^{3'}$, and $R^{4'}$ are respectively equivalent to a group R^1, R^{68}, R^{67} and R^4 as defined in claim 11 or a precursor thereof, and R^{85} is a leaving group, with a compound of formula (VIII)

$$H\text{-}X\text{-}R^{8''}$$

(VIII)

where X, is as defined in claim 11, and $R^{8''}$ is



where Z, n, R^6, R^7 and R^9 are as defined in claim 11.

13-14. (Canceled)

15. (Currently amended) A pharmaceutical composition comprising a compound of formula (IIB) as defined in claim 11, or a salt ~~or prodrug~~ thereof, in combination with a pharmaceutically acceptable carrier.

16. (Currently amended) A compound according to claim 11 or a salt ~~or prodrug~~ thereof wherein R^1 and R^4 are both hydrogen.

17. (Previously presented) A compound according to claim 11 wherein R^{67} is 3-morpholinopropoxy.

18. (Previously presented) A compound according to claim 11 wherein R^6 and R^7 are independently selected from hydrogen, halo, C_{1-4}alkoxy, cyano, trifluoromethyl or phenyl.

19. (Previously presented) A compound according to claim 11 wherein R^6 and R^7 are both hydrogen.

20. (Cancelled)

21. (Currently amended) A method of treating colorectal or breast cancer in a warm blooded animal comprising administering to said animal an effective amount of a compound according to claim 11 or a salt ~~or prodrug~~ thereof.